ProMIS Neurosciences Inc.
Close on Oct 19, 2026
- Market cap
- $75.24M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
Press releases
Announcements ProMIS Neurosciences filed with the SEC
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRECISE-AD PMN310 · PHASE 1b
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential
Regulation FD disclosure · EX-99.1 to Form 8-K
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Reports Promising Top-Line Data from its Phase 1a Alzheimer's Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences, Inc. Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Announces $20.4 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
Other events · EX-99.1 to Form 8-K
of Investigational New Drug (IND) Application for Lead Antibody PMN310
Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Announces Third Quarter 2022 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Closing of US
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
ProMIS Neurosciences Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K